These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15582006)

  • 1. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
    Büyükçelik A; Yalçin B; Utkan G; Doruk H
    Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
    Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2004 Jun; 93(3):699-701. PubMed ID: 15196867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
    Caponigro F; Willemse P; Sorio R; Floquet A; van Belle S; Demol J; Tambaro R; Comandini A; Capriati A; Adank S; Wanders J
    Invest New Drugs; 2005 Jan; 23(1):85-9. PubMed ID: 15528985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.
    Kurzeder C; Sauer G; Deissler H
    Curr Cancer Drug Targets; 2006 May; 6(3):207-27. PubMed ID: 16712458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to chemotherapy in ovarian carcinoma.
    Lage H; Denkert C
    Recent Results Cancer Res; 2007; 176():51-60. PubMed ID: 17607916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
    Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
    Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
    Sessa C; Del Conte G
    Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrent ovarian cancer.
    Tummala MK; McGuire WP
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):723-36. PubMed ID: 16224447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of taxane resistance genes with the clinical course of ovarian carcinoma.
    Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R
    Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation: Bay-59-8862.
    Eckstein JW
    IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
    Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
    Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
    Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
    Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
    Verschraegen CF; Levenback C; Vincent M; Wolf J; Bevers M; Loyer E; Kudelka AP; Kavanagh JJ
    Ann N Y Acad Sci; 2000; 922():349-51. PubMed ID: 11193920
    [No Abstract]   [Full Text] [Related]  

  • 16. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
    Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
    Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
    Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
    Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors reverse taxane resistance.
    Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
    Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral cytotoxic drugs.
    Gridelli C; Rossi A; Guerriero C; Nicolella D; Ferrara C; Del Gaizo F; Colantuoni G; Airoma G; Maione P
    Suppl Tumori; 2002; 1(4):S19-23. PubMed ID: 12415809
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
    Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.